Yichun Xu

Dr. Yichun Xu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
YXYichun Xu
Yichun Xu
JZJiajing Zhou
Jiajing Zhou
QYQing Yuan
Qing Yuan
JSJun Su
Jun Su
QLQian Li
Qian Li
JHJunsong Han
Junsong Han
Liquid biopsy represents a diagnostic and monitoring tool and the circulating cell-free mitochondrial DNA (mtDNA) plays a vital role in tumor diagnosis and dynamic assessment. Colorectal cancer (CRC) is one of the most common fatal cancers worldwide. Mitochondrially encoded NADH dehydrogenase subunit 1 (MT-ND1) encodes the biggest subunit of respiratory complex I of mtDNA, and mutations in the MT-ND1 are common in CRC. We sought to determine if mutations in circulating MT-ND1 could be a potential biomarker for colorectal cancer. In this study, twenty-two CRC patients at Zhujiang Hospital were included. We mainly used droplet digital PCR to determine the mutation status of MT-ND1, combined with clinical data. In the experiment in vivo, cell-free mtDNA generally presented high concordance with tumor tissues. By quantitative PCR, the MT-ND1 content of plasma in CRC patients was significantly higher than that in healthy individuals (58.01 vs. 0.64, p=0.027). The detection of circulating MT-ND1 content and variants (m.3606 A>G, m.3970 C>T, m.4071 C>T, m.4086 C>T) in cfDNA showed a good correlation with predicted tumor response and progression to chemotherapy. In conclusion, the content and variants of circulating MT-ND1 may become a versatile tool for the diagnosis and monitoring of the colorectal cancer.

29 August 2023 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
YXYichun Xu
Yichun Xu
JSJun Su
Jun Su
JZJia-Jing Zhou
Jia-Jing Zhou
QYQing Yuan
Qing Yuan
JHJunsong Han
Junsong Han

21 December 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
KLKecheng Lei
Kecheng Lei
LZLiwen Zhang
Liwen Zhang
YHYijing He
Yijing He
HSHui Sun
Hui Sun
WTWeifang Tong
Weifang Tong
LJLingjing Jin
Lingjing Jin
Early stage diagnosis of Parkinson’s disease (PD) is challenging without significant motor symptoms. The identification of effective molecular biomarkers as a hematological indication of PD may help improve the diagnostic timelines and accuracy. In the present paper, we analyzed and compared the blood samples of PD and control (CTR) patients to identify the disease-related changes and determine the putative biomarkers for PD diagnosis. Based on the RNA sequencing analysis, differentially expressed genes (DEGs) were identified, and the co-expression network of DEGs was constructed using the weighted gene correlation network analysis (WGCNA). The analysis leads to the identification of 87 genes that were exclusively regulated in the PD group, whereas 66 genes were significantly increased and 21 genes were significantly decreased in contrast with the control group. The results indicate that the core lncRNA–mRNA co-expression network greatly changes the immune response in PD patients. Specifically, the results showed that Prader Willi Angelman Region RNA6 (PWAR6), LINC00861, AC83843.1, IRF family, IFIT family and calcium/calmodulin-dependent protein kinase IV (CaMK4) may play important roles in the immune system of PD. Based on the findings from the present study, future research aims at identifying novel therapeutic strategies for PD.

10 April 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YXYichun Xu
Yichun Xu
YYYong Yang
Yong Yang
YWYichao Wang
Yichao Wang
JSJun Su
Jun Su
TCTianlong Chan
Tianlong Chan
JHJunsong Han
Junsong Han
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer with high morbidity and mortality rates. Due to the heterogeneity of LUAD, its characteristics remain poorly understood. Exploring the clinical and molecular characteristics of LUAD is challenging but vital for early diagnosis. Methods: This observational and validation study enrolled 80 patients and 13 healthy controls. Nuclear and mtDNA-captured sequencings were performed. Results: This study identified a spectrum of nuclear and mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with diagnosis. The correlation coefficient for somatic mutations in cfDNA and patient-matched tumor tissues was high in nuclear and mitochondrial genomes. The mutation number of highly mutated genes was evaluated, and the Least Absolute Shrinkage and Selection Operator (LASSO) established a diagnostic model. Receiver operating characteristic (ROC) curve analysis explored the diagnostic ability of the two panels. All models were verified in the testing cohort, and the mtDNA panel demonstrated excellent performance. This study identified somatic mutations in the nuclear and mitochondrial genomes, and detecting mutations in cfDNA displayed good diagnostic performance for early-stage LUAD. Moreover, detecting somatic mutations in the mitochondria may be a better tool for diagnosing early-stage LUAD. Conclusions: This study identified specific and sensitive diagnostic biomarkers for early-stage LUAD by focusing on nuclear and mitochondrial genome mutations. This also further developed an early-stage LUAD-specific mutation gene panel for clinical utility. This study established a foundation for further investigation of LUAD molecular pathogenesis.

10 December 2025 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
JSJun Su
Jun Su
JQJingjing Qiu
Jingjing Qiu
JMJiaxu Meng
Jiaxu Meng
YGYi Gong
Yi Gong
YXYichun Xu
Yichun Xu
JHJunsong Han
Junsong Han
Respiratory disease, such as lung cancer, is a major risk factor that seriously endangers human health. In the development of new drugs, conventional precl

1 December 2016 in Gene
Verified
Journal Article
Closed access
ZCZhai Cai
Zhai Cai
SHShuai Han
Shuai Han
ZLZhou Li
Zhou Li
LHLinyun He
Linyun He
JZJiajing Zhou
Jiajing Zhou
YXYichun Xu
Yichun Xu